立体定向放疗在超中央型肺癌治疗中的应用进展  

Advances in stereotactic body radiation therapy for ultra-central lung cancer

作　　者：于旭耀 王煜雯(综述) 宋勇春(审校) Xuyao Yu;Yuwen Wang;Yongchun Song(Department of Radiation Oncology,Tianjin Medical University Cancer Institute&Hospital,National Clinical Research Center for Cancer,Tianjin's Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin 300060,China;Department of Radiotherapy,Airport Hospital,Tianjin Medical University Cancer Institute&Hospital,Tianjin 300060,China)

机构地区：[1]天津医科大学肿瘤医院放射治疗科国家恶性肿瘤临床医学研究中心天津市恶性肿瘤临床医学研究中心天津市肿瘤防治重点实验室,天津市300060 [2]天津医科大学肿瘤医院空港医院放射治疗科

出　　处：《中国肿瘤临床》2023年第2期104-108,共5页Chinese Journal of Clinical Oncology

基　　金：中国博士后基金项目(编号:2019M661039);天津市卫生健康科技项目(编号:TJWJ2021QN009);天津医科大学肿瘤转化医学种子基金项目(编号:1903)资助。

摘　　要：立体定向放射治疗(stereotactic body radiation therapy,SBRT)可实现不可手术超中央型肺癌(ultra-central lung cancer,UCLC)患者的靶区高剂量照射并较好保护危及器官,是目前临床治疗的探索热点。接受SBRT治疗后UCLC患者可获得较好的局部控制率、中位生存时间和总生存率,但是由于UCLC紧邻或侵犯纵隔内重要脏器,SBRT治疗会常伴有一定的不良反应风险。本文就SBRT应用于UCLC患者的临床实践及研究进展进行综述。Stereotactic body radiation therapy(SBRT)can achieve high-dose irradiation in the target areas of patients with ultra-central lung cancer(UCLC)while also protecting the surrounding organs at risk.SBRT is the gold standard of clinical treatment for patients with UCLC.Some clinical studies on SBRT for UCLC treatment have shown that it can obtain a better local control rate,median survival time,and overall survival rate than other known treatment methods.However,because UCLC tissues are close to organs at risk in the patient’s mediastinum,SBRT treatment is often accompanied by toxicity and side effects.This article reviews the progress of research on SBRT for the treatment of patients with UCLC.

关 键 词：超中央型肺癌 立体定向体部放射治疗 处方剂量 危及器官 不良反应 

分 类 号：R734.2[医药卫生—肿瘤]